Nakashima Chiho, Sato Akemi, Abe Tomonori, Kato Junichi, Hirai Mitsuharu, Nakamura Tomomi, Komiya Kazutoshi, Sueoka Eisaburo, Kimura Shinya, Sueoka-Aragane Naoko
Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.
Department of Clinical Laboratory Medicine, Faculty of Medicine, Saga University, Saga, Japan.
Oncotarget. 2018 May 18;9(38):25181-25192. doi: 10.18632/oncotarget.25388.
The clinical utility of plasma DNA for detecting cancer-specific mutations has rapidly achieved recognition, but reliability has not been established because of relatively low mutation-detection rates compared with those from tissue re-biopsy. To address this shortcoming we examined efficiency, in terms of mutation detection, of an automated DNA extraction system that uses cellulose magnetic beads. A fully automated, highly sensitive point-mutation-detection method, mutation-biased PCR and quenching probe (MBP-QP) system, was used for this study. Plasma DNA was extracted from 61 plasma samples collected from patients with advanced non-small cell lung cancer. Extraction was performed manually with 200 μl plasma (200-M) by using a silica membrane spin column system or an automated system using 200 μl (200-A) or 1000 μl (1000-A) plasma. Median DNA yield quantified by real-time PCR was 4.4, 4.5, and 17.3 ng with the three methods, respectively. Sensitivity for detecting epidermal growth factor receptor () L858R point mutation was 36.6%, 58.5%, and 77.5%, and specificity was 93.3%, 100%, and 96.7%, respectively. Concordance rates were 60.6%, 76.1%, and 85.7%. The size distribution of plasma DNA with automated extraction was bimodal with modes at about 170 bp and 5 Kb, and plasma DNA of both sizes included tumor-derived DNA. In this report, we demonstrate that automated DNA extraction using cellulose magnetic beads can improve mutation-detection rates with plasma DNA in association with two overall sizes of DNA fragments recovered by this DNA isolation system. Examining the biological characteristics of these fragments will be the subject of further investigation.
血浆DNA用于检测癌症特异性突变的临床效用已迅速得到认可,但由于与组织重新活检相比突变检测率相对较低,其可靠性尚未确立。为解决这一缺点,我们研究了一种使用纤维素磁珠的自动化DNA提取系统在突变检测方面的效率。本研究采用了一种全自动、高灵敏度的点突变检测方法,即突变偏向PCR和淬灭探针(MBP-QP)系统。从61例晚期非小细胞肺癌患者采集的血浆样本中提取血浆DNA。使用硅胶膜离心柱系统对200μl血浆进行手动提取(200-M),或使用自动化系统对200μl(200-A)或1000μl(1000-A)血浆进行提取。通过实时PCR定量的三种方法的DNA产量中位数分别为4.4、4.5和17.3 ng。检测表皮生长因子受体(EGFR)L858R点突变的灵敏度分别为36.6%、58.5%和77.5%,特异性分别为93.3%、100%和96.7%。一致性率分别为60.6%、76.1%和85.7%。自动化提取的血浆DNA的大小分布呈双峰,峰值分别在约170 bp和5 Kb处,两种大小的血浆DNA均包含肿瘤来源的DNA。在本报告中,我们证明使用纤维素磁珠的自动化DNA提取可以提高血浆DNA的突变检测率,同时与通过该DNA分离系统回收的两种总体大小的DNA片段相关。研究这些片段的生物学特性将是进一步研究的主题。